


Collaborations Pharmaceuticals, Inc. Announces Major Updates to 2022 Pipeline

Collaborations Pharmaceuticals, Inc. (CPI) announced major updates to their drug discovery research and development pipeline aided by machine learning software.

RALEIGH, NORTH CAROLINA, USA, May 18, 2022 /EINPresswire.com/ -- "At a time when many small to mid-size pharmaceutical and biotech companies are trimming down their research and development pipelines, we are going in the opposite direction. This also comes at a time when larger companies are looking for assets to bolster their own pipelines. Several recent drug discovery projects at CPI have now been completed and we will be

reporting their data in due course in peer reviewed publications said Dr. Sean Ekins, CEO, CPI." "Notable amongst these are the completion of the Batten disease (enzyme replacement therapy), Chagas Disease, COVID-19 and Acute Flaccid Myelitis preclinical in vivo studies. Most of this late stage preclinical work has been funded via grants from the NIH to CPI or through NIH contracts to third parties. In addition, we have advanced several more projects through the in vitro stages of drug discovery. Most recently we have initiated an early stage NIDA funded project on generating novel non-addictive psychoplastogens in order to develop treatments for opioid abuse disorder."

"What is apparent is the wide impact [machine learning software](#) is having on our [pipeline](#) as nearly all the projects have used our [Assay Central](#) software. This is also an enabling technology that we actively license to other companies and provide for use on fee-for-service projects. We are also open to partnering with other companies or organizations to advance the treatments in our pipeline for various rare and neglected diseases." "To date the company has been funded by fee-for service work, grant funding and matching grants from the One North Carolina SBIR/STTR Matching Funds Program. We would be happy to work with larger companies that could benefit



from our expertise in building drug discovery pipelines and creating value using machine learning technologies for drug discovery, stated Dr. Ekins”.

Sean Ekins

Collaborations Pharmaceuticals, Inc.

+1 215-687-1320

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/572881063>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.